Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 253

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 253
---
”) under the 2020 CLAs.

<div align='center'>F-9</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 4:- | CONVERTIBLE NOTES (Cont.) |

On January 3, 2024, the Company extended
the due date until April 30, 2024 and, subsequently on April 26, 2024 further extended the due date until May 27, 2024. In October 2024,
the Company signed an addendum to the 2020 CLA agreement to extend the maturity date until March 31, 2025 (see also Note 8).

The Company estimates the fair value
of the 2020 Notes using the Probability-Weighted Expected Return Method (“PWERM”). For the six months ended June 30, 2024
and 2023, the Company recorded an income of $4,867 and an expense of $2,046 for the revaluation of such 2020 Notes, within financial
income, net in the statements of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   |  June 30, 
      2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------|:----|:--|----------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |       900 |   |     | $ |          900 |   |
| Discount rate    |     |   |        30 | % |     |   |           30 | % |
| Term (years)     |     |   | 0.75-0.92 |   |     |   |         0.25 |   |
| Fair value       |     |   |     2,538 |   |     |   |        7,405 |   |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy.

The Company recalculated the fair
value of the 2020 Notes by applying a +/- 5.0% changes to the